NHS Greater Glasgow and Clyde

Scotland's legal go-ahead for safer drug consumption rooms is a gamechanger

Retrieved on: 
Saturday, September 16, 2023
Misuse of Drugs Act 1971, Lord, HIV, Solution, NHS Greater Glasgow and Clyde, Policy, Health and Social Care Partnership, Research, Aircraft, History, Lord Advocate, Government, Abuse, Drug, Environment, News, Drug-related deaths in the United Kingdom, GameChanger, Pharmaceutical industry, Interior design, Medical device

Dorothy Bain KC, Lord Advocate of Scotland Scotland’s most senior law officer, the Lord Advocate, has released a statement that would enable NHS Glasgow and Clyde to open a safer drug consumption facility (SDCF) in the city.

Key Points: 
  • Dorothy Bain KC, Lord Advocate of Scotland Scotland’s most senior law officer, the Lord Advocate, has released a statement that would enable NHS Glasgow and Clyde to open a safer drug consumption facility (SDCF) in the city.
  • Also known as overdose prevention centres, SDCFs are spaces where people can take their own drugs under supervision.
  • They also provide non-judgmental settings where people who use drugs can access wider support or be directed to other services.
  • Safer consumption rooms are viewed by many as a critical element of this broader response.

Changing approaches to drug harms

    • The request was declined on the basis that what it sought was too broad and beyond the remit of the Lord Advocate.
    • Last year a new, narrower request was put to the current Lord Advocate, Dorothy Bain.
    • The Scottish secretary Alister Jack has since confirmed that “the UK government will not intervene” to prevent a safer consumption room being established.

An essential first step

    • It is of enormous significance and will be welcomed by many across the UK who believe these centres can play a vital role in tackling drug harms.
    • The terms of the Lord Advocate’s statement are, however, strictly constrained.
    • It applies specifically to the Glasgow pilot and is based on assessment of its particular design, setting and operating procedures.
    • If we are to really understand the role safer consumption rooms can play in tackling drug harms, we need multiple pilots and evaluations.

Indica Labs Announces Collaboration with The Industrial Centre for Artificial Intelligence Research in Digital Diagnostics (iCAIRD) for the Development of an AI-based Algorithm for the Automated Reporting of Lymph Node Status in Colon Cancer

Retrieved on: 
Tuesday, August 30, 2022
Patient, Medical laboratory, Research, Diagnosis, Technology, Cancer, AP, UK Research and Innovation, Program, SME, ISCF, Innovation, National Health Service, Artificial intelligence, Food Industry Centre, UKRI, Solution, LIS, Innovate UK, Pathology, NHS Greater Glasgow and Clyde, Colorectal cancer, Precision medicine, Marie Cassidy, Colorectal surgery, Radiology, Intelligence, NHS, Large intestine, Deep learning, Lymph, HALO, Tor (anonymity network), Efficiency, Prostate cancer, Industry, AI, NHSGGC, Medical imaging, Medical device, Indica

The mission of iCAIRD is to establish a world-class center of excellence for implementation of artificial intelligence in digital diagnostics.

Key Points: 
  • The mission of iCAIRD is to establish a world-class center of excellence for implementation of artificial intelligence in digital diagnostics.
  • Anonymized H&E slides from NHS Greater Glasgow and Clyde's digital pathology archive will be used to train, validate and test the algorithm, which is being developed collaboratively by iCAIRD and Indica Labs.
  • The resulting algorithm will report negative and positive lymph node status and will be compared to pathologist reports.
  • Through this collaboration, diagnostic accuracy and efficiency will be compared between existing fully digital workflows and one that applies AI through HALO AP.

Galvani Bioelectronics Announces World’s First Investigational Treatment of Rheumatoid Arthritis Using Splenic Nerve Stimulation

Retrieved on: 
Thursday, January 27, 2022
General Health, Health, Medical Devices, University, Joint, Therapy, Galvani Bioelectronics, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Trial of the century, Partnership, Bioelectronics, Software, COO, Conditional sentence, Population, Senior, FDA, Degenerative disease, MHRA, Spleen, Peripheral nervous system, Multimedia, Research, NHS Greater Glasgow and Clyde, Food, Health care, Luigi Galvani, University of Texas Southwestern Medical Center, Physician, Safety, Inflammation, GSK, Disease, Electronics, IDE, Pharmaceutical industry, Medical device, Vaccine, GlaxoSmithKline, Development, Medicine, Verily, Rheumatoid arthritis

Splenic nerve stimulation generates nerve signals to the spleen which in turn have been shown to shift splenic immune cells from a pro-inflammation to an inflammation-resolving state.

Key Points: 
  • Splenic nerve stimulation generates nerve signals to the spleen which in turn have been shown to shift splenic immune cells from a pro-inflammation to an inflammation-resolving state.
  • We look forward to bringing the wide-ranging potential of splenic nerve stimulation to the clinic as a hopeful new treatment option for people suffering with rheumatoid arthritis, said Stephen Gillett, President and COO of Verily and Galvani Board Director.
  • To learn more about Splenic Nerve Stimulation for RA, visit https://www.SplenicStimulationforRa.com/ or to see more about the clinical studies visit (US) NCT05003310 or (UK) NCT04955899 .
  • The Galvani Bioelectronics platform is available for investigational use only and it is not approved for use outside of clinical studies.

Scotland's NHS Greater Glasgow and Clyde Health Board Seeks Better Use of Data and Increased Participation in Clinical Trials by Joining TriNetX Network

Retrieved on: 
Thursday, December 17, 2020
Geography of Scotland, Scotland, Glasgow, NHS Scotland, NHS Greater Glasgow and Clyde, National Health Service

"We've joined the TriNetX network to improve the way we use data to drive research across NHSGGC and with our partner organizations.

Key Points: 
  • "We've joined the TriNetX network to improve the way we use data to drive research across NHSGGC and with our partner organizations.
  • TriNetX offers the fastest growing collaborative research network representing over 170 healthcare organizations (HCOs) and health data partners, spanning 30 countries.
  • "Greater Glasgow and Clyde is a highly respected NHS organization," said Steve Lethbridge, Senior Vice President of Global Healthcare Partnerships at TriNetX.
  • For further information about the health board, please visit the NHS Greater Glasgow and Clyde website .

Storm ID and Zebra Medical Vision to Co-Develop Revolutionary New AI Based Osteoporosis Prevention Solution as Part Of UK-Israel Collaboration

Retrieved on: 
Monday, November 23, 2020
Technology, Medical devices, Hospitals, Software, Other Health, Biotechnology, Radiology, Health, Data management, Consumer electronics, Organ systems, Endocrine diseases, Bone fractures, Osteopathies, Aging-associated diseases, Osteoporosis, Pathologic fracture, Bone fracture, Storm ID and Lenus Health, Zebra Medical Vision, NHS Greater Glasgow and Clyde, Assuta Medical Centers, EUREKA

The collaboration will involve close engagement with clinical teams in NHS Greater Glasgow and Clyde and Assuta Medical Centers .

Key Points: 
  • The collaboration will involve close engagement with clinical teams in NHS Greater Glasgow and Clyde and Assuta Medical Centers .
  • View the full release here: https://www.businesswire.com/news/home/20201123006272/en/
    Storm ID and Zebra Medical Vision to co-develop revolutionary new AI based osteoporosis prevention solution as part of UK-Israel collaboration (Photo: Business Wire)
    Osteoporosis is a major public health concern that continues to grow in worldwide importance.
  • Fragility fractures, defined as insufficiency fractures not related to high-impact trauma, are the major complication of this underdiagnosed and undertreated condition.
  • Working in partnership, Storm ID and Zebra Medical Vision are developing a preventative care solution to identify people at risk of osteoporosis.